Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

References

• . Trivedi MH, Rush AJ, Wisniewski SR,. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40
   PubMed Web of Science ®Google Scholar
• . Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62(11):1217–1227
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Trivedi MH, Wisniewski SR,. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917
   PubMed Web of Science ®Google Scholar
• . Judd LL, Akiskal HS, Maser JD,. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2–3):97–108
   PubMed Web of Science ®Google Scholar
• . Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2): 131–161
   PubMed Web of Science ®Google Scholar
• . Abilify (aripiprazole) tablets; Abilify Discmelt (aripiprazole) orally disintegrating tablets; Abilify (aripiprazole) oral solution, Abilify (aripiprazole) injection for intramuscular use only. New York, NY: Bristol-Myers Squibb; Rockville, MD: Otsuka America Pharmaceuticals, Inc. Product label, revised November 2009. http://www.abilify.com/pdf/pi.aspx. Accessed January 2010
   Google Scholar
• . Zyprexa (olanzapine) tablet for oral use; Zyprexa Zydis (olanzapine) tablet, orally disintegrating for oral use; Zyprexa intramuscular (olanzapine) injection powder, solution for intramuscular use. Indianapolis, IN: Eli Lilly and Company. Product label, revised December 4, 2009. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed January 2010
   Google Scholar
• . Symbax (olanzapine and fluoxetine hydrochloride) capsule for oral use. Indianapolis, IN: Eli Lilly and Company. Product label, revised August 31, 2009. http://pi.lilly.com/us/symbyax-pi.pdf. Accessed January 2010
   Google Scholar
• . Seroquel XR (quetiapine fumarate) extended-release tablets. Product label revised December 2009. Wilmington, DE: AstraZeneca Pharmaceuticals, LP. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed January 2010
   Google Scholar
• . Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419
   PubMed Web of Science ®Google Scholar
• . Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3): 229–237
   PubMedGoogle Scholar
• . Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother. 2008;8(7):1079–1091
   PubMedGoogle Scholar
• . Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof. 2002;25(2):210–224
   PubMed Web of Science ®Google Scholar
• . Berman RM, Fava M, Thase ME,. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197–206
   PubMed Web of Science ®Google Scholar
• . Marcus RN, McQuade RD, Carson WH,. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165
   PubMed Web of Science ®Google Scholar
• . Berman RM, Marcus RN, Swanink R,. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–853
   PubMed Web of Science ®Google Scholar
• . Thase ME, Corya SA, Osuntokun O,. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224–236
   PubMed Web of Science ®Google Scholar
• . Shelton RC, Tollefson GD, Tohen M,. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134
   PubMed Web of Science ®Google Scholar
• . Shelton RC, Williamson DJ, Corya SA,. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289–1297
   PubMed Web of Science ®Google Scholar
• . Corya SA, Williamson D, Sanger TM,. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364–372
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Thase ME, Osuntokun O,. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70(3):387–396
   PubMed Web of Science ®Google Scholar
• . Bauer M, Pretorius HW, Constant E,. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540–549
   PubMed Web of Science ®Google Scholar
• . El-Khalili N, Joyce M, Atkinson S,. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study [published online ahead of print February 23, 2010]. Int J Neuropsychopharmacol.
   Google Scholar
• . Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990–996
   PubMed Web of Science ®Google Scholar
• . Citrome L. Relative vs absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand. 2010;121(2):94–102
   PubMed Web of Science ®Google Scholar
• . Sackett DL, Rosenberg WM, Gray JA,. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71–72
   PubMed Web of Science ®Google Scholar